Literature DB >> 18725442

In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.

James A Karlowsky1, Nancy M Laing, George G Zhanel.   

Abstract

Agar dilution antimicrobial susceptibility testing (CLSI, M11-A7, 2007) performed for 208 toxin-producing clinical isolates of Clostridium difficile resulted in OPT-80 MICs ranging from 0.06 to 1 microg/ml, with 90% of the isolates inhibited by a concentration of 0.5 microg/ml. The in vitro activity of OPT-80 was independent of the susceptibilities of isolates to nine other antimicrobial agents.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18725442      PMCID： PMC2573132          DOI： 10.1128/AAC.00476-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  In vitro activities of OPT-80 and comparator drugs against intestinal bacteria.

Authors:  Sydney M Finegold; Denise Molitoris; Marja-Liisa Vaisanen; Yuli Song; Chengxu Liu; Mauricio Bolaños
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 2.  Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee.

Authors:  R Fekety
Journal:  Am J Gastroenterol       Date:  1997-05       Impact factor: 10.864

Review 3.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

4.  Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.

Authors:  Daniel M Musher; Saima Aslam; Nancy Logan; Srikanth Nallacheru; Imran Bhaila; Franziska Borchert; Richard J Hamill
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

5.  Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

Authors:  Jacques Pepin; Marie-Eve Alary; Louis Valiquette; Evelyne Raiche; Joannie Ruel; Katalin Fulop; Dominique Godin; Claude Bourassa
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

Review 6.  Recommendations for preventing the spread of vancomycin resistance.

Authors: 
Journal:  Infect Control Hosp Epidemiol       Date:  1995-02       Impact factor: 3.254

7.  Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity.

Authors:  R J Theriault; J P Karwowski; M Jackson; R L Girolami; G N Sunga; C M Vojtko; L J Coen
Journal:  J Antibiot (Tokyo)       Date:  1987-05       Impact factor: 2.649

8.  Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanism of action.

Authors:  S Sergio; G Pirali; R White; F Parenti
Journal:  J Antibiot (Tokyo)       Date:  1975-07       Impact factor: 2.649

9.  In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.

Authors:  R N Swanson; D J Hardy; N L Shipkowitz; C W Hanson; N C Ramer; P B Fernandes; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

10.  Lipiarmycin-resistant ribonucleic acid polymerase mutants of Bacillus subtilis.

Authors:  A L Sonenshein; H B Alexander; D M Rothstein; S H Fisher
Journal:  J Bacteriol       Date:  1977-10       Impact factor: 3.490
View more
  15 in total

Review 1.  Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Authors:  Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

2.  Fidaxomicin: in Clostridium difficile infection.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 3.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

Review 4.  Clostridium difficile infection: new insights into management.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Mayo Clin Proc       Date:  2012-11       Impact factor: 7.616

5.  Recent new drug approvals, part 2: drugs undergoing active clinical studies in children.

Authors:  Rebecca F Chhim; Chasity M Shelton; Michael L Christensen
Journal:  J Pediatr Pharmacol Ther       Date:  2013-01

6.  Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

Authors:  Farah Babakhani; Abraham Gomez; Nikki Robert; Pamela Sears
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

7.  Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.

Authors:  D R Snydman; N V Jacobus; L A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

8.  Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.

Authors:  Ellie J C Goldstein; Diane M Citron; Pamela Sears; Farah Babakhani; Susan P Sambol; Dale N Gerding
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

Review 9.  Clostridium difficile infection: management strategies for a difficult disease.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Therap Adv Gastroenterol       Date:  2014-03       Impact factor: 4.409

10.  Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea.

Authors:  Yoav Golan; Lauren Epstein
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.